Roche will acquire PathAI for $750 million upfront plus milestones of up to $300 million, expanding its digital pathology, oncology diagnostics, precision medicine, and biopharma capabilities.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Roche has entered into a definitive merger agreement to acquire PathAI, a US-based company focused on digital pathology and artificial intelligence-powered technology for pathology laboratories and the biopharma industry. The transaction is expected to close in the second half of 2026, subject to customary regulatory and antitrust approvals.
Under the terms of the agreement, Roche will pay $750 million upfront, with additional milestone payments of up to $300 million. Following the completion of the transaction, PathAI will become part of Roche’s Diagnostics division.
The acquisition is intended to strengthen Roche’s position in digital pathology and advance its broader effort to transform AI-driven diagnostics. Digital pathology involves the creation of high-resolution digital images from tissue slides, enabling pathologists to use AI-based tools to support diagnostic workflows and potentially improve efficiency and turnaround times for patients.
Roche and PathAI have collaborated since 2021, with the partnership expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms. Roche said the acquisition will further integrate PathAI’s technology into its broader oncology diagnostics portfolio and support its move toward more personalized healthcare.
Matt Sause, CEO of Roche Diagnostics, said digital pathology could improve precision diagnosis of cancer and help physicians deliver better tailored treatment regimens. He added that combining PathAI’s digital pathology tools with Roche’s oncology diagnostics platforms could improve clinical insights and patient outcomes worldwide.
PathAI’s AISight image management system (IMS) offers advanced AI analysis and workflow capabilities for digital pathology laboratories. Roche said it plans to scale the platform globally as demand for digital pathology solutions continues to grow across the pathology market.
The acquisition is also expected to strengthen Roche’s precision medicine and biopharma services capabilities. Roche said PathAI’s expertise in AI-driven clinical trial support and translational research complements its companion diagnostics business and could support biomarker discovery, the identification of potential drug targets, and the development of novel diagnostic tools, while also accelerating clinical therapy development.
Andy Beck, CEO and Co-Founder of PathAI, said the agreement with Roche would help expand the company’s AI-powered pathology technologies globally and accelerate efforts to improve patient outcomes through digital diagnostics.
Reference
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
About the Writer
Samiksha Vikram Jadhav (LinkedIn) is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.
